Use of Catalyst Pharmacophore Models for Screening of Large Combinatorial Libraries

Using a data set comprised of literature compounds and structure-activity data for cyclin dependent kinase 2, several pharmacophore hypotheses were generated using Catalyst and evaluated using several criteria. The two best were used in retrospective searches of 10 three-dimensional databases containing over 1,000,000 proprietary compounds. The results were then analyzed for the efficiency with which the hypotheses performed in the areas of compound prioritization, library prioritization, and library design. First as a test of their compound prioritization capabilities, the pharmacophore models were used to search combinatorial libraries that were known to contain CDK active compounds to see if the pharmacophore models could selectively choose the active compounds over the inactive compounds. Second as a test of their utility in library design again the pharmacophore models were used to search the active combinatorial libraries to see if the key synthons were over represented in the hits from the pharmacophore searches. Finally as a test of their ability to prioritize combinatorial libraries, several inactive libraries were searched in addition to the active libraries in order to see if the active libraries produced significantly more hits than the inactive libraries. For this study the pharmacophore models showed potential in all three areas. For compound prioritization, one of the models selected active compounds at a rate nearly 11 times that of random compound selection though in other cases models missed the active compounds entirely. For library design, most of the key fragments were over represented in the hits from at least one of the searches though again some key fragments were missed. Finally, for library prioritization, the two active libraries both produced a significant number of hits with both pharmacophore models, whereas none of the eight inactive libraries produced a significant number of hits for both models.

[1]  L Jeppesen,et al.  1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists. , 1998, Journal of medicinal chemistry.

[2]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 1. Validation and Estimation of Coverage , 1995, J. Chem. Inf. Comput. Sci..

[3]  Andrew Smellie,et al.  Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..

[4]  M. Wick,et al.  Synthesis and activity of 2,6,9-trisubstituted purines , 1997 .

[5]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[6]  Thomas Meyer,et al.  Structure-based design of potent CDK1 inhibitors derived from olomoucine , 2000, J. Comput. Aided Mol. Des..

[7]  D. Boschelli,et al.  Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. , 2000, Journal of medicinal chemistry.

[8]  P. Sprague.  Automated chemical hypothesis generation and database searching with Catalyst , 1995 .

[9]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[10]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[11]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[12]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 2. Applications of Conformational Models , 1995, J. Chem. Inf. Comput. Sci..

[13]  P. Worland,et al.  Structure-activity relationship studies of flavopiridol analogues. , 2000, Bioorganic & medicinal chemistry letters.

[14]  S L Lin,et al.  Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. , 1997, Journal of medicinal chemistry.

[15]  Malcolm J. McGregor,et al.  Pharmacophore Fingerprinting. 1. Application to QSAR and Focused Library Design , 1999, J. Chem. Inf. Comput. Sci..

[16]  Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. , 1999, Journal of medicinal chemistry.

[17]  Arup K. Ghose,et al.  Pharmacophore Modelling: Methods,Experimental Verification and Applications , 2002 .

[18]  W. Humphreys,et al.  Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. , 2000, Journal of medicinal chemistry.

[19]  M C Nicklaus,et al.  HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. , 1997, Journal of medicinal chemistry.

[20]  G L Trainor,et al.  Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. , 2000, Journal of medicinal chemistry.

[21]  Malcolm J. McGregor,et al.  Pharmacophore Fingerprinting. 2. Application to Primary Library Design , 2000, J. Chem. Inf. Comput. Sci..

[22]  Jean M. J. Tronchet,et al.  A QSAR Study of the Antimalarial Activity of Some Synthetic 1, 2, 4-Trioxanes , 1997, J. Chem. Inf. Comput. Sci..

[23]  M. Wigler,et al.  Complex synthetic chemical libraries indexed with molecular tags. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[25]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[26]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[27]  P. Traxler,et al.  Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. , 1999, Journal of medicinal chemistry.